scholarly journals Bone-specific alkaline phosphatase and bone turnover in African American hemodialysis patients

2016 ◽  
Vol 21 (1) ◽  
pp. 90-96 ◽  
Author(s):  
Lenar Yessayan ◽  
Carol Moore ◽  
Mei Lu ◽  
Jerry Yee
Keyword(s):  
Alkaline Phosphatase ◽  
African American ◽  
Bone Turnover ◽  
Hemodialysis Patients ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase

scholarly journals Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: Is it so simple?

2013 ◽  
Vol 417 ◽  
pp. 35-38 ◽  
Author(s):  
Pierre Delanaye ◽  
Bernard E. Dubois ◽  
François Jouret ◽  
Jean-Marie Krzesinski ◽  
Olivier Moranne ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Turnover ◽  
Hemodialysis Patients ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase

scholarly journals Changes in Bone Turnover in Young Women Consuming Different Levels of Dietary Protein1

1999 ◽  
Vol 84 (3) ◽  
pp. 1052-1055 ◽  
Author(s):  
Jane E. Kerstetter ◽  
MaryAnn E. Mitnick ◽  
Caren M. Gundberg ◽  
Donna M. Caseria ◽  
Alice F. Ellison ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Resorption ◽  
Bone Turnover ◽  
Young Women ◽  
Dietary Protein ◽  
Urinary Calcium ◽  
Calcium Excretion ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Low Protein

Although high protein diets are known to increase urinary calcium excretion and induce negative calcium balance, the impact of dietary protein on bone turnover and fractures is controversial. We therefore evaluated the effect of dietary protein on markers of bone turnover in 16 healthy young women. The experiment consisted of 2 weeks of a well balanced diet containing moderate amounts of calcium, sodium, and protein followed by 4 days of an experimental diet containing one of three levels of protein (low, medium, or high). On day 4, serum and urinary calcium, serum PTH, 1,25-dihydroxyvitamin D, serum osteocalcin, bone-specific alkaline phosphatase, and urinary N-telopeptide excretion were measured. Urinary calcium excretion was significantly higher on the high than on the low protein diet. Secondary hyperparathyroidism occurred on the low protein diet. Urinary N-telopeptide excretion was significantly greater during the high protein than during the low protein intake (48.2 ± 7.2 vs. 32.7 ± 5.3 nM bone collagen equivalents/mM creatinine; P < 0.05). There was no increase in osteocalcin or bone-specific alkaline phosphatase when comparing the low to the high diet, suggesting that bone resorption was increased without a compensatory increase in bone formation. Our data suggest that at high levels of dietary protein, at least a portion of the increase in urinary calcium reflects increased bone resorption.

scholarly journals Decreased Nitric Oxide Levels and Bone Turnover in Amenorrheic Athletes with Spinal Osteopenia1

1998 ◽  
Vol 83 (9) ◽  
pp. 3056-3061 ◽  
Author(s):  
E. Stacey ◽  
P. Korkia ◽  
M. V. J. Hukkanen ◽  
J. M. Polak ◽  
O. M. Rutherford
Keyword(s):  
Nitric Oxide ◽  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
No Production ◽  
Mineral Density ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase

Amenorrheic athletes have been likened to postmenopausal women, with low estrogen levels and osteopenia. It has been suggested that estrogen exerts its antiresorptive actions on bone via a nitric oxide (NO)-dependent mechanism. This study investigated whether the mechanism of bone loss in amenorrheic athletes is similar to that of postmenopausal women with reduced NO levels and high bone turnover. Eleven amenorrheic athletes, 15 eumenorrheic athletes, and 10 sedentary controls were studied. Spine and hip bone mineral density was measured using dual-energy x-ray absorptiometry. Bone turnover was assessed by biochemical markers of formation (osteocalcin and bone-specific alkaline phosphatase) and resorption (deoxypyridinoline). NO metabolites were measured from 24-h urine samples using a chemiluminescence assay. Spine, but not hip, bone mineral density was reduced in the amenorrheic group, compared with the eumenorrheic (P = 0.0001) and control (P = 0.04) groups. Osteocalcin, bone-specific alkaline phosphatase, and deoxypyridinoline were similar in all groups. NO metabolites were lower in the amenorrheic group, compared with controls (P = 0.035), despite a higher dietary intake of nitrates. Unlike postmenopausal women, amenorrheic athletes do not have raised bone turnover but do have reduced NO metabolites and spinal osteopenia. The results show, however, that reduced NO production is a common denominator in both conditions and further support the importance of NO in estrogen-mediated protection of skeletal mass and strength.

scholarly journals Effects of Soy Isoflavones on Markers of Bone Turnover in Premenopausal and Postmenopausal Women*

2000 ◽  
Vol 85 (9) ◽  
pp. 3043-3048 ◽  
Author(s):  
Kerry E. Wangen ◽  
Alison M. Duncan ◽  
Barb E. Merz-Demlow ◽  
Xia Xu ◽  
Robert Marcus ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Soy Isoflavones ◽  
Type I ◽  
Small Magnitude ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Markers Of Bone Turnover ◽  
Cross Links

Abstract Soy isoflavones are hypothesized to exert hormonal effects in women and thus may play a role in bone metabolism throughout life. In 2 randomized, cross-over studies, 14 pre- and 17 postmenopausal women were given 3 soy protein isolates containing different amounts of isoflavones [control, 0.13; low isoflavone (low-iso), 1.00; and high-iso, 2.01 mg/kg body wt·day, averaging 8, 65, and 130 mg/day, respectively], for over 3 months each. Food records, blood samples, and 24-h urine collections were obtained throughout the studies. The endpoints evaluated included plasma or serum concentrations of bone-specific alkaline phosphatase, osteocalcin, insulin-like growth factor-I (IGFI), IGF binding protein-3 (IGFBP3), and urine concentrations of deoxypyridinoline cross-links and carboxy-terminal telopeptide of type I collagen. In premenopausal women, IGFI and IGFBP3 concentrations were increased by the low-iso diet, and deoxypyridinoline cross-links was increased by both the low- and high-iso diets during certain phases of the menstrual cycle. In postmenopausal women, bone-specific alkaline phosphatase was decreased by both the low- and high-iso diets, and there were trends toward decreased osteocalcin, IGFI, and IGFBP3 concentrations with increasing isoflavone consumption. Although soy isoflavones do affect markers of bone turnover, the changes observed were of small magnitude and not likely to be clinically relevant. These data do not support the hypothesis that dietary isoflavones per se exert beneficial effects on bone turnover in women.

scholarly journals The Effect of Bed Rest on Bone Turnover in Young Women Hospitalized for Anorexia Nervosa: A Pilot Study

2009 ◽  
Vol 94 (5) ◽  
pp. 1650-1655 ◽  
Author(s):  
Amy D. DiVasta ◽  
Henry A. Feldman ◽  
Ashley E. Quach ◽  
Maria Balestrino ◽  
Catherine M. Gordon
Keyword(s):  
Alkaline Phosphatase ◽  
Anorexia Nervosa ◽  
Bone Formation ◽  
Bone Turnover ◽  
Weight Bearing ◽  
Tertiary Care ◽  
Bed Rest ◽  
Short Term ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase

Abstract Context: Malnourished adolescents with anorexia nervosa (AN) requiring medical hospitalization are at high risk for skeletal insults. Even short-term bed rest may further disrupt normal patterns of bone turnover. Objective: The objective of the study was to determine the effect of relative immobilization on bone turnover in adolescents hospitalized for AN. Design: This was a short-term observational study. Setting: The study was conducted at a tertiary care pediatric hospital. Study Participants: Twenty-eight adolescents with AN, aged 13–21 yr with a mean body mass index of 15.9 ± 1.8 kg/m2, were enrolled prospectively on admission. Intervention: As per standard care, all subjects were placed on bed rest and graded nutritional therapy. Main Outcome Measure: Markers of bone formation (bone specific alkaline phosphatase), turnover (osteocalcin), and bone resorption (urinary N-telopeptides NTx) were measured. Results: During the 5 d of hospitalization, serum osteocalcin increased by 0.24 ± 0.1 ng/ml · d (P = 0.02). Urine N-telopeptides reached a nadir on d 3, declining −6.9 ± 2.8 nm bone collagen equivalent per millimole creatinine (P = 0.01) but returned to baseline by d 5 (P > 0.05). Bone-specific alkaline phosphatase exhibited a decline that was strongly age dependent, being highly significant for younger subjects only [age 14 yr: −0.42 ± 0.11 (P = 0.0002); age 18 yr: −0.03 ± 0.08 (P = 0.68)]. Age had no effect on other outcome measures. Conclusion: Limitation of physical activity during hospitalization for patients with AN is associated with suppressed bone formation and resorption and an imbalance of bone turnover. Future interventional studies involving mechanical stimulation and/or weight-bearing activity are needed to determine whether medical protocols prescribing strict bed rest are appropriate.

Effect of the ERα agonist GTx-758 on bone turnover markers in men with advanced prostate cancer.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 222-222
Author(s):  
Evan Y. Yu ◽  
Thomas E. Keane ◽  
Ronald Tutrone ◽  
Laurence Belkoff ◽  
Joel Bass ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Alkaline Phosphatase ◽  
Bone Turnover ◽  
Phase Ii ◽  
Advanced Prostate Cancer ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Markers Of Bone Turnover ◽  
Venous Thromboembolic Events

222 Background: Men with advanced prostate cancer are being treated with androgen deprivation therapy (ADT) for longer periods of time. The use of ADT can be limited by estrogen deficiency side effects, including a loss of bone and a higher incidence of fractures. GTx-758 is an ERα agonist that lowers serum free testosterone greater than an LHRH agonist. Herein we compare the effects of GTx-758 and leuprolide on markers of bone turnover, C-terminal telopeptides and bone specific alkaline phosphatase, in men with advanced prostate cancer treated with ADT. Methods: In a Phase II study (G200705), men with advanced prostate cancer (n=159) received 1000 mg or 2000 mg of GTx-758 daily or leuprolide. Serum samples were collected and analyzed by a reference laboratory. C-terminal telopeptides (pg/ml) and bone specific alkaline phosphatase (U/L) were measured as indicators of bone turnover. All p values describe the comparison of the GTx-758 treatment groups to the leuprolide treated men at day 120. Results: Men receiving the 1000 mg and 2000 mg doses of GTx-758 had lower C-terminal telopeptide levels with a mean percentage change of -56.9 ± 12.5 and -54.8 ± 23.1, respectively, as compared with an increase of 46.0 ± 48.9 percentage in the men receiving the leuprolide (p<0.001). Similarly, bone specific alkaline phosphatase levels were lower in men treated with GTx-758, with mean percentage changes of-28.5 ± 11.7 and -19.8 ± 14.7, respectively, compared with an increase of 8.1 ± 24.3 percent in the leuprolide treated group (p<0.001). As a result of an increased risk of venous thromboembolic events (VTEs) at these higher doses of GTx-758, the trial was stopped prior to its completion and not all of the men on the study reached the 120 day treatment dates (71 evaluable). Conclusions: Patients receiving GTx-758 experienced a significant decrease in markers of bone turnover indicating potential improvement and not a loss of bone on ADT. Since changes in bone mineral density are a major side effect that can negatively affect the quality of life in men on ADT, the improvements in bone turnover observed in men treated with GTx-758 could be significant. A Phase II clinical trial utilizing lower doses of GTx-758 (G200712) is currently being performed. Clinical trial information: NCT01326312.

Sign in / Sign up

Export Citation Format

Share Document